Development of therapeutic approaches to 'triple negative' phenotype breast cancer

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 9, 2008, Pages 1123-1137

  Shiu, Kai Keen ^a   Tan, David S P ^a   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Basal like cancer; BRCA; Platinum; Poly(ADP ribose) polymerase inhibitors; Targeted therapy; Triple negative

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BIOLOGICAL PRODUCT; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM COMPLEX; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND INHIBITOR; UNINDEXED DRUG;

ADJUVANT THERAPY; APOPTOSIS; BREAST CANCER; CANCER CLASSIFICATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FATIGUE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER TOXICITY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PHENOTYPE;

EID: 51549089009     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.9.1123     Document Type: Review

References (123)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869-74
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418-23
4. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109(1):25-32
5. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329-34
6. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-34
7. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49(1):22-34
8. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19(2):264-71
9. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9(5):R65. Published online 2 October 2007, doi:10.1186/bcr1771
10. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49(1):10-21
11. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11(14):5175-80
12. Lamovec J, Us-Krasovec M, Zidar A, Kljun A. Adenoid cystic carcinoma of the breast: a histologic, cytologic, and immunohistochemical study. Semin Diagn Pathol 1989;6(2):153-64
13. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunchistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474-81
14. Bertucci I, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123(1):236-40
15. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;2492-502
16. Gamel JW, Meyer JS, Feuer E, Miller BA. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast carcinoma. Cancer 1996;77(8):1459-64
17. van de Vijver MJ. The pathology of familial breast cancer: the pre-BRCA1/ BRCA2 era: historical perspectives. Breast Cancer Res 1999;1(1):27-30
18. Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 2006;8(6):R66. Published online 27 November 2006, doi:10.11861bcr1622
19. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24(36):5652-7
20. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9(1):R4. Published online 11 January 2007, doi:10.1186/bcr1636
21. Rodriguez-Pinilta SM, Sarrio D, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12(5):1533-9
22. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30(9):1097-104
23. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275-81
24. Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008;26(5):798-805
25. Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol 2008;26(5):745-52
26. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84
27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72
28. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100(18):10393-8
29. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-85
30. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res 2008;14(2):618; author reply 618-9
31. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10(16):5367-74
32. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14(5):1368-76
33. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52(1):108-18
34. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26(15):2568-81
35. Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006;8(2):R23. Published online 20 April 2006, doi:10.1186/bcr1399
36. Bidard FC, Conforti R, Boulet T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007;18(7):1285-6
37. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64(3):830-5
38. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96. Published online 27 April 2006, doi:10.1186/1471-2164-7-96
39. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006;19(2):307-19
40. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13(1):90-101
41. Charafe-Jauffret E, Monville F, Bertucci F, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007;121(8):1779-85
42. Sitterding SM, Wiseman WR, Schiller CL, et al. αB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 2008;12(1):33-40
43. Moyano JV, Evans JR, Chen F, et al. αB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006;116(1):261-70
44. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13(4):1198-207
45. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006;5(2):135-42
46. Curtin N. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin Ther Targets 2007;11(6):783-99
47. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21
48. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48
49. Hosey AM, Gorski JJ, Murray MM, et al. Molecular basis for estrogen receptor a deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007;99(22):1683-94
50. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25(43):5846-53
51. Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006;25(43):5837-45
52. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26(14):2126-32
53. Lambie H, Miremadi A, Pinder SE, et al. Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 2003;200(2):207-13
54. Rakha EA, El-Sheikh SE, Kandil MA, et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008;39(6):857-65
55. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92(7):564-9
56. Osin P, Lu YJ, Stone J, et al. Distinct genetic and epigenetic changes in medullary breast cancer. Int J Surg Pathol 2003;11(3):153-8
57. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev 2004;4(10):814-9
58. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res 2006;12(15):4463-8
59. McCarthy A, Savage K, Gabriel A, et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007;211(4):389-98
60. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104(29):12111-6
61. Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2007: published online 6 October 2007, doi:10.1007/s10549-007-9756-8
62. Conforti R, Boulet T, Tomasic G, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007;18(9):1477-83
63. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, mediotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8(9):1483-96
64. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83
65. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357(15):1496-506
66. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24(36):5664-71
67. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13
68. Ellis PA, Barrett-Lee PJ, Bloomfield D, et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) trial [abstract 78]. Breast Cancer Res Treat 2007;106(Suppl 1):S21
69. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13(24):7413-20
70. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008;108(2):289-96
71. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (New York), NY 1999;286(5442):1162-6
72. Tibbetts RS, Cortez D, Brumbaugh KM, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 2000;14(23):2989-3002
73. Lee JS, Collins KM, Brown AL, et al. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404(6774):201-4
74. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14(8):927-39
75. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96(22):1659-68
76. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25(43):5864-74
77. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88(8):1285-91
78. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63(19):6221-8
79. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275(31):23899-903
80. Rottenberg S, Nygren AO, Pajic M, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007;104(29):12117-22
81. Yap T, Boss D, Fong P, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers [abstract 3529]. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl)
82. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract 2006;3(8):448-57
83. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004; 10(1 Pt 1): 178-83
84. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22(24)
85. Shepherd F, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
86. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209(4):445-53
87. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7(6):R1028-35
88. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
89. Cunningham D, Humbler Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-45
90. Hoadley KA, Weigman VJ, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258. Published online 31 July 2007, doi:10.1186/1471-2164-8-258
91. Grimaldi AM, Guida T, D'Arrino R, et al. Sunitinib: bridging present and future cancer treatment. Ann Oncol 2007;18(Supp] 6):vi31-4
92. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2(10):1011-21
93. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of Sunitinib Malate, an oral mullitargeted cyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26(11):1810-6
94. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105(3):319-26
95. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531-41
96. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22(6):1200-6
97. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180(4):383-8
98. Myoui A, Nishimura R, Williams PJ, et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 2003;63(16):5028-33
99. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67(5):2226-38
100. Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008;110(2):245-56
101. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
102. Ribeiro-Silva A, Ribeiro do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am J Clin Pathol 2006;125(4):512-8
103. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, rumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57(5):963-9
104. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
105. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
106. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously created metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24
107. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
108. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9
109. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast (Edinburgh, Scotland) 2007;16(Suppl 2):S17-9
110. Rahman M, Davis SR, Pumphrey JG, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2008; published online 1 February 2008, doi:10.1007/ s10549-008-9924-5
111. Tolcher AW, Mica M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand recepror-1. J Clin Oncol 2007;25(11):1390-5
112. Kendrick JE, Estes JM, Straughn JM Jr, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol 2007;106(3):614-21
113. Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59(3):734-41
114. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24(26):4236-44
115. Yehiely F, Moyano JV, Evans JR, et al. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006;12(11):537-44
116. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest J Tech Methods Pathol 2007;87(8):737-54
117. Bost WJ. Systems biology by the rules: hybrid intelligent systems for pathway modeling and discovery. BMC Syst Biol 2007;1:13. Published online 15 February 2007, doi:10.1186/1752-0509-1-13
118. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Bio Syst 2006;83(2-3):81-90
119. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12(22):6652-62
120. Cheng KW, Lahad JP, Kuo WL, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004;10(11):1251-6
121. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6(7):556-68
122. Tan D, Reis-Filho J. Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast Cancer. Pathobiology 2008;75(2):63-74
123. Available from: http://clinicaltrials.gov [Accessed on 8 April 2008]